Article info

Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain

Authors

  1. Correspondence to Laura Salinas-Ortega, Pharmacoeconomics and Outcomes Research Iberia, Pozuelo de Alarcón 28224, Spain; lsalinas{at}porib.com
View Full Text

Citation

Calleja MA, Albanell J, Aranda E, et al
Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain

Publication history

  • Received July 8, 2021
  • Accepted November 1, 2021
  • First published November 22, 2021.
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.